UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~October~~November, 2025

Commission File Number: 001-42155

	Ping An Biomedical Co., Ltd.
	(Registrant’s Name)

22/F, China United Plaza, 1002-1008, Tai Nan West Street,

Cheung Sha Wan, Kowloon, Hong Kong

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~INFORMATION~~Nasdaq ~~CONTAINED~~Minimum INBid ~~THIS~~Price ~~REPORT~~Deficiency ~~ON FORM 6-K~~Letter

~~Resignation~~On November 24, 2025, Linkers Industries Limited. (the “Company”) received a letter from the Listing Qualifications staff of ~~Chairman~~The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, ~~Chief~~2025 ~~Executive~~to ~~Officer~~November 20, ~~Chief~~2025, ~~Financial~~the ~~Officer~~Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), ~~Executive~~to ~~Director~~maintain a ~~and~~minimum ~~Independent~~bid ~~Directors~~price of $1 per share.

InNasdaq ~~October~~has ~~2025,~~provided the ~~Board~~ ofCompany ~~Directors~~with ~~(the~~an ~~“Board”)~~180 ofcalendar ~~Ping~~days Ancompliance ~~Biomedical Co.~~period, ~~Ltd.~~or ~~(the~~until ~~“Company”)~~May ~~received~~25, ~~and~~2026, ~~accepted~~in ~~the~~which ~~resignation of~~to ~~Ms.~~regain ~~Yuk~~compliance ~~Yin~~with ~~Judy~~Nasdaq Licontinued ~~from~~listing requirement. ~~her~~In ~~position~~the asevent that the ~~Chairman~~Company ~~and~~does ~~Director~~not ofregain ~~the~~compliance ~~Board~~in of the ~~Company~~compliance period, the ~~resignation~~Company ofmay ~~Ms.~~be ~~Lina~~eligible ~~Jiang~~for ~~from~~an additional ~~her~~180 ~~position~~calendar asdays, should the ~~Director~~Company ofmeet the ~~Board~~continued ~~and~~listing ~~Chief~~requirement ~~Executive~~for ~~Officer~~market value of ~~the~~publicly ~~Company,~~held ~~the~~shares ~~resignation~~and ofall ~~Ms.~~other ~~Xueyuan~~initial listing ~~Chen~~standards ~~from~~for ~~her~~The ~~position as~~Nasdaq ~~the~~Capital ~~Chief~~Market, ~~Financial~~with ~~Officer~~the exception of the ~~Company~~bid ~~and~~price ~~Mr.~~requirement, ~~Taylor~~and ~~Carl~~is ~~Coplen~~able ~~from~~to ~~his~~provide ~~position~~written ~~as independent director~~ notice of ~~the~~its ~~Board, all~~intention ~~effective~~to ~~immediately.~~cure ~~Each~~the ofdeficiency ~~Ms.~~during ~~Yuk~~the ~~Yin~~second ~~Judy~~compliance Liperiod, ~~Ms.~~by ~~Lina~~effecting ~~Jiang,~~a ~~Ms.~~reverse ~~Xueyuan~~stock ~~Chen~~split, ~~and~~if Mrnecessary. ~~Taylor~~However, if ~~Carl~~it ~~Coplen~~appears ~~resigned~~that ~~for~~the ~~personal reasons~~Company ~~and~~will not ~~due~~be able to ~~any~~cure ~~disagreement~~the ~~with~~deficiency, or if the Company oris ~~the~~otherwise ~~Board~~not oneligible, ~~any~~Nasdaq ~~matter~~will ~~relating~~provide notice tothat the Company’s ~~operations,~~securities ~~policies, or~~will ~~practices~~be subject to delisting.

~~Appointment~~The ofCompany ~~Chairman,~~is ~~Chief~~currently evaluating ~~Financial~~options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although ~~Officer~~the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), ~~Executive~~there ~~Director~~can ~~and~~be ~~Independent~~no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement. ~~Director~~

~~Effective~~On ~~October~~November 1428, 2025, the ~~Board~~Company ~~appointed~~issued ~~Mr. Pijun Liu as~~ a ~~Chairman~~press ofrelease ~~the~~discussing ~~Board of~~ the ~~Company,~~receipt ~~Chief Executive Officer~~ of the ~~Company,~~deficiency ~~and the Executive Director of the Board~~letter, ~~Ms.~~which ~~Hongli~~is ~~Yang~~filed as aexhibit ~~Chief Financial Officer of the Company and Mr~~99.1 ~~Xianzhi~~to ~~Liu~~this ~~as independent director of the~~Form ~~Board~~6-K.

~~Mr.~~Financial ~~Pijun Liu, male, born~~Statements ~~in 1982, holds Chinese nationality. He graduated from Wuhan University of Technology with a bachelor’s degree~~ and ~~earned a master’s degree in Computer and Information Technology from the University of Arizona in the United States~~Exhibits. From 2018 to 2020, he pursued postgraduate studies at the School of Finance, Renmin University of China, and later attended the EMBA program at Tsinghua Five College of Economics and Management. From 2004 to 2007, served as a project manager at ELong.com. From 2014 to 2023, served as the founder and CEO of Yueshang Group, receiving investments.

~~Ms.~~The ~~Hongli~~following ~~Yang,~~exhibits ~~female,~~are ~~was born~~being infiled 1995 and holds Chinese nationality. She graduated from Xiangtan University, majoring in Financial Management, and obtained a bachelor’s degree. Since 2021, she has successively served as the Chief Financial Officer at Softcom Information Technology (Group) Co., Ltd., Beijing Sinobo Information Technology Co., Ltd., and Huibo Cloud Communication Technology Co., Ltd. In these positions, she has comprehensively coordinated the management work of the finance department.herewith:

Mr. Xianzhi Liu, male, born in 1997, is a Chinese national with no permanent residence abroad. He graduated from North University of China with a bachelor’s degree in Electronic Science and Technology and from the University of Leeds with a master’s degree in Mechatronics and Robotics. In 2022, he worked at JD.com, Inc. From 2023 to 2024, he was employed at Beijing New Oriental Education Consulting Co., Ltd. Since 2025, he has been working at New Channel (Zhejiang Headquarters).

Exhibit No.		Description
99.1		Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PING AN BIOMEDICAL CO., LTD.
Date: October 14, 2025	By:	/s/ Pijun Liu
Date: November 28, 2025	By:	/s/ Pijun Liu
	Name:	Pijun Liu
	Title:	Chairman of the Board of Directors

Filing Compare · Ping An Biomedical Co., Ltd.